Purchase this article with an account.
Aurelien Freton, Kimberley Chin, Robert Rout, Lawrence B. Tena, Paul T. Finger; PET/CT for Initial Screening of Metastatic Uveal Melanoma: Analysis of 333 Patients. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3285.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report our experience with whole body Positron Emission Tomography/Computed Tomography (PET/CT) screening for metastatic uveal melanoma.
333 consecutive patients were diagnosed with uveal melanoma and underwent screening for metastatic disease with PET/CT and liver function tests. PET/CT results suspicious for metastatic melanoma prompted further biopsies, blood tests, imaging and/or clinical evaluations for confirmation.
Seven of 333 (2.1%) patients were found to have metastatic choroidal melanoma. Ten (3.3%) were diagnosed with synchronous second cancers and 28 (8.4%) had benign lesions. The most common metastatic sites were liver (n=7), osseous (n=2), lungs, brain, spleen, lymph nodes and subcutaneous tissue (each n=1). Liver function tests were within normal limits in all metastatic patients. Using AJCC-UICC tumor staging criteria, one of the primary tumors was classified as T3, and 6 were T4. By COMS criteria, there was 1 medium and 6 large melanomas. PET/CT significantly improved the yield of metastases detection in T4 tumors in comparison to previous reports.
Our findings support the use of PET/CT as a screening procedure for metastatic disease in uveal melanoma patients, especially in patients with large tumors that present an increased risk for patent metastatic disease at time of diagnosis.
This PDF is available to Subscribers Only